PRCT NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Procept Biorobotics Corp · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 18.62 USD
11.6% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -26.0% below the Trend Line and sits at 5.7% of its 52-week range. The latest completed week returned 11.6%, after a -11.5% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is mixed with 28/100 conviction, while the latest news-sentiment score is 44/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 13 out of 100
Latest Close 18.62 USD 31 Jul 2026
1W Return 11.6% latest completed week
4W Return -11.5% short-term follow-through
12W Return -26.7% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 11.6% Latest completed week; four-week move -11.5%. Indicator stack 0/16 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.89% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 28/100 conviction; expected move 19.3%. News sentiment 44/100 64 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -26.0% below the Trend Line and sits at 5.7% of its 52-week range. The latest completed week returned 11.6%, after a -11.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1212-week average 0.16

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.12Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -11.5% over four weeks, -26.7% over 12 weeks, and -62.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W11.6%
4W-11.5%
12W-26.7%
26W-35.7%
52W-62.7%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.63Latest activity-pressure read.
Pressure change-282.0%Four-week change in activity pressure.
Leadership-42.80Latest relative-leadership reading.
RS change3.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength4/100Blend of value, momentum, and quality. Underlying universe rank 97; rank 1 is best.
Value27/100Relative valuation strength. Underlying universe rank 74; rank 1 is best.
Quality7/100Profitability and accounting quality. Underlying universe rank 94; rank 1 is best.
Momentum3/100Medium-term price momentum. Underlying universe rank 98; rank 1 is best.
Growth82/100Revenue and earnings growth. Underlying universe rank 19; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
63.0%
Gross profit retained from each unit of revenue.
Operating margin
-30.7%
Operating profit retained from revenue.
Free-cash-flow margin
-18.5%
Free cash flow generated from revenue.
Return on invested capital
-48.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
29.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
2.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

PRCT shows mixed options pressure with a 28/100 conviction score, put-call volume ratio of 0.93, expected move of 19.3%, and Sharemaestro trend signal inactive.

Conviction28/100
Expected move19.3%
Put/call volume0.93
Pressure11
Speculation5
Volatility96
Trend agreement48
Open options detail
Insider activity16 / 3

16 acquisitions and 3 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment44/100

Weighted news tone is neutral across 64 relevant articles.

10 positive · 36 neutral · 18 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move19.3%Nearest-chain priced movement where available.
52-week drawdown-63.6%Distance below the 52-week high.
13-week volatility8.5%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+12.0%Week of 13 Mar.
Worst week-16.8%Week of 27 Feb.
Latest week+11.6%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks0
Modest losses5
Sharp losses10
Recent vol8.5%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew5.1% / -6.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape14/100

Trend, activity pressure, participation, and risk combine to a 14/100 tape read.

 Indicator analysis26/100

Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.

Activity pressure 0.12; No reversal markers Next-Week ExpectancyNegative 42.89%

Next-week expectancy is negative with a 42.89% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors9/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 59; Small Cap Core rank 74 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

PRCT shows mixed options pressure with a 28/100 conviction score, put-call volume ratio of 0.93, expected move of 19.3%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 19.3% Sentiment44/100

Weighted news tone is neutral across 64 relevant articles.

PROCEPT BioRobotics Corporation (PRCT) Investors: September 22, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP Insiders16 / 3

16 acquisitions and 3 disposals in the latest 180-day insider tape.

 Earnings2d

Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.62 USD11.6%25.16 USD48.48 USD-0.63-42.806.3MOff
24 Jul 202616.69 USD-13.2%25.57 USD48.59 USD-0.51-49.746.8MOff
17 Jul 202619.22 USD-8.0%26.09 USD48.71 USD-0.14-44.689.1MOff
10 Jul 202620.89 USD-0.7%26.52 USD48.83 USD0.05-44.027.7MOff
3 Jul 202621.03 USD-6.8%27.02 USD48.93 USD0.35-44.175.5MOff
26 Jun 202622.56 USD3.9%27.52 USD49.03 USD0.67-41.209.5MOff
19 Jun 202621.72 USD-15.5%27.82 USD49.12 USD0.77-47.2811.3MOff
12 Jun 202625.70 USD-7.6%28.09 USD49.19 USD0.95-37.787.4MOff
5 Jun 202627.83 USD5.7%28.22 USD49.25 USD1.01-32.885.0MOff
29 May 202626.33 USD-9.2%28.36 USD49.29 USD0.94-40.904.6MOff
22 May 202629.00 USD11.0%28.62 USD49.33 USD0.89-34.616.9MOff
15 May 202626.12 USD2.8%28.82 USD49.34 USD0.60-41.7111.6MOff
8 May 202625.40 USD3.1%29.05 USD49.38 USD0.27-44.765.7MOff
1 May 202624.63 USD1.1%29.30 USD49.41 USD0.00-44.7010.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.